Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03326245 · ClinicalTrials.gov registry record · Phase 1
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
A Phase 1 study of Normal Physiology, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03326245: Completed Phase 1 study of Normal Physiology, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT03326245 is a Phase 1 study of Normal Physiology that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 25 participants, below the 1,292-participant average among 25 other Normal Physiology trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03326245, a Phase 1 study of Normal Physiology, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug. They want to learn how methylphenidate and brain dopamine affect body responses, mood, and thinking. Objective: To better understand the role of dopamine in the brain and the effects of methylphenidate. Eligibility: Adults ages 18-55 who have used alcohol or stimulant drugs but have no drug dependence. Design: Participants will be screened with: * Physical exam * Question about medical, psychiatric, and alcohol and drug use history * Questions to see if it s safe to have a PET/MRI scan * Blood and urine tests * Breath test for alcohol Participants will have 3 or 4 study visits. At each visit they will have: * Urine and breath tested for alcohol and drugs * A thin plastic tube (catheter) inserted in each arm by needle * A small amount of radioactive chemical injected through the catheter. * PET/MRI scan. Participants will lie still on a table that slides in and out of a metal cylinder surrounded by a strong magnetic field. Their vital signs will be monitored. They will get earmuffs for loud noises. Before the scan, participants will get the study drug or placebo through the catheter. They may also get a sugar pill (placebo). They will get a small meal and have blood drawn. * Tests of memory, attention, and thinking. Participants will wear an activity monitor on the wrist for one week.
Primary Outcome
Participants underwent brain positron emission tomography (PET) scan with \[11C\]raclopride. The SUVR is calculated by dividing the standardized uptake value in the putamen, target region, by the standardized uptake value in the cerebellum, the reference region. This ratio normalizes the uptake values and allows for comparisons between individuals or across different imaging sessions.
Conditions Studied
Interventions
- DRUG Oral Placebo
- DRUG Intravenous Placebo
- DRUG Methylphenidate Pill
- DRUG Intravenous methylphenidate
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 1 |
What the finished NCT03326245 record still lists
NCT03326245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,292-participant average among 25 other Normal Physiology trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Normal Physiology appearing as the primary indexed condition, and to 4 interventions - of which Oral Placebo is the first listed.
NCT03326245 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03326245 about?
NCT03326245 is a clinical study titled "Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI". Background: Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug. They want to learn how methylphenidate and brain dopamine affect body res...
What is the current status of trial NCT03326245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2018-01-29. Estimated completion is 2024-02-08.
What conditions does trial NCT03326245 study?
This clinical trial studies the following conditions: Normal Physiology.
What interventions are being tested in trial NCT03326245?
The interventions under investigation include: Oral Placebo (DRUG), Intravenous Placebo (DRUG), Methylphenidate Pill (DRUG), Intravenous methylphenidate (DRUG).
Who is sponsoring clinical trial NCT03326245?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03326245 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Normal Physiology
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03326245's enrollment target sits among peer trials
25 25th of 25 higher than 1 of 25 other Normal Physiology trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Normal Physiology trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Investigating the Impact of Obesity on Pubertal Development in Girls
RECRUITING
-
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
RECRUITING · NA
-
Influence of Brain Oscillation-Dependent TMS on Motor Function
RECRUITING
-
Sociocultural & Biobehavioral Influences on Pain Expression and Assessment
RECRUITING · NA
-
Clinical and Scientific Assessment of Pain and Painful Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI